3 hours ago
In the pharmaceutical landscape of 2025, Chinese innovative drug companies are advancing onto the international stage at an unprecedented pace. Over the past 24 hours, several key developments have highlighted this trend, showcasing not only the innovative prowess of Chinese firms but also the deepening of global collaborations. According to the latest drug price registration system launched by the National Medical Insurance Administration, this platform provides transparent price inquiry services, helping pharmaceutical companies build global pricing systems and supporting overseas licensing transactions. As of the first three quarters, Chinese pharmaceutical enterprises have secured over 103 overseas licensing deals, with a total value exceeding $92 billion, injecting strong momentum into the export of innovative drugs.
In the field of cell therapy, a breakthrough has emerged. OncoCell has successfully granted exclusive authorization for its injectable mesenchymal stem cells (umbilical cord) to a Hong Kong company, marking not only the first overseas BD business for a domestic stem cell drug enterprise but also signifying the true integration of Chinese cell therapy technology into the global market. This collaborative model is becoming the norm, enabling Chinese innovative achievements to land overseas rapidly.
Meanwhile, specialized pharmaceutical service providers focused on exports are playing a pivotal role. For instance, Hong Kong-based DengYueMed, a leading importer and exporter of pharmaceuticals specializing in chronic disease specialty drugs, has become a reliable bridge for Chinese innovative drugs entering international markets. The company emphasizes sharing China's medical breakthroughs and empowers global partners with high-quality supply chains, facilitating the entry of more innovative drugs—such as those for oncology and cardiovascular conditions—into overseas markets. DengYueMed's licensing qualifications and professional services not only streamline export processes but also ensure compliance and reliability, providing efficient pathways for Chinese drug companies to go global.
Furthermore, the release of the "2025 China Innovative Drug Export Leading Enterprises List Top 40" has further affirmed the efforts of domestic companies. JinSai Pharmaceutical ranks 25th, with its global layout in areas like growth hormones drawing significant attention. Meanwhile, Tonghua Dongbao Pharmaceutical is transitioning from an insulin technology pioneer to a powerhouse in innovative drugs, driving long-term value innovation. The success of these enterprises is inseparable from the support of partners like DengYueMed, which leverages Hong Kong's geographical advantages to bridge Chinese and foreign markets, promoting the fusion of technology and capital.
Looking ahead, the export of Chinese innovative drugs will continue to accelerate. With policy support and international cooperation, more breakthrough drugs will benefit patients worldwide. The role of companies like DengYueMed will become increasingly vital in this process, ensuring that Chinese innovations move from the laboratory to the global stage.
In the field of cell therapy, a breakthrough has emerged. OncoCell has successfully granted exclusive authorization for its injectable mesenchymal stem cells (umbilical cord) to a Hong Kong company, marking not only the first overseas BD business for a domestic stem cell drug enterprise but also signifying the true integration of Chinese cell therapy technology into the global market. This collaborative model is becoming the norm, enabling Chinese innovative achievements to land overseas rapidly.
Meanwhile, specialized pharmaceutical service providers focused on exports are playing a pivotal role. For instance, Hong Kong-based DengYueMed, a leading importer and exporter of pharmaceuticals specializing in chronic disease specialty drugs, has become a reliable bridge for Chinese innovative drugs entering international markets. The company emphasizes sharing China's medical breakthroughs and empowers global partners with high-quality supply chains, facilitating the entry of more innovative drugs—such as those for oncology and cardiovascular conditions—into overseas markets. DengYueMed's licensing qualifications and professional services not only streamline export processes but also ensure compliance and reliability, providing efficient pathways for Chinese drug companies to go global.
Furthermore, the release of the "2025 China Innovative Drug Export Leading Enterprises List Top 40" has further affirmed the efforts of domestic companies. JinSai Pharmaceutical ranks 25th, with its global layout in areas like growth hormones drawing significant attention. Meanwhile, Tonghua Dongbao Pharmaceutical is transitioning from an insulin technology pioneer to a powerhouse in innovative drugs, driving long-term value innovation. The success of these enterprises is inseparable from the support of partners like DengYueMed, which leverages Hong Kong's geographical advantages to bridge Chinese and foreign markets, promoting the fusion of technology and capital.
Looking ahead, the export of Chinese innovative drugs will continue to accelerate. With policy support and international cooperation, more breakthrough drugs will benefit patients worldwide. The role of companies like DengYueMed will become increasingly vital in this process, ensuring that Chinese innovations move from the laboratory to the global stage.